Hydroxychloroquine does not counter SARS-CoV-2 in hamsters, high dose of favipiravir does

(KU Leuven) Virologists from the KU Leuven Rega Institute in Belgium have shown that a treatment with the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in hamsters. A high dose of the anti-flu drug favipiravir, by contrast, has an antiviral effect in the hamsters. The team published their findings in the Proceedings of the National Academy of Sciences (PNAS).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Steve Lindsay, a public health entomologist at Durham University, is midway through explaining how dogs might play a role in detecting COVID-19 infections when a decidedly less-well trained canine interrupts our conversation. “If you’ll excuse me for a minute, I’ve got a naughty black Labrador out in the back garden doing something it shouldn’t be doing,” Lindsay says. He disappears. I hear barking. He returns accompanied by a chocolate lab. “She’s not as skilled as the detection dogs,” Lindsay says as the pup tries to lick his face. “But it’s really interesting t...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
We present advances in modeling techniques that have led to fundamental disease discoveries and impacted clinical translation.Recent FindingsCombining mechanistic models and machine learning algorithms has led to improvements in the treatment ofShigella and tuberculosis through the development of novel compounds. Modeling of the epidemic dynamics of malaria at the within-host and between-host level has afforded the development of more effective vaccination and antimalarial therapies. Similarly, in-host and host-host models have supported the development of new HIV treatment modalities and an improved understanding of the i...
Source: Current Pathobiology Reports - Category: Laboratory Medicine Source Type: research
This article focuses on the impact of the COVID-19 pandemic on child health in sub-Saharan Africa. We review the epidemiology of major pediatric diseases and, referencing modeling projections, discuss the short- and long-term impact of the pandemic on major disease control. We deliberate on potential complications of SARS-CoV-2 co-infections/co-morbidities and identify critical social and ethical issues. Furthermore, we highlight the paucity of COVID-19 data and clinical trials in this region and the lack of child participants in ongoing studies. Lastly, approaches and interventions to mitigate the pandemic's impact on chi...
Source: Pediatric Research - Category: Pediatrics Authors: Tags: Pediatr Res Source Type: research
Abstract The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a lim...
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharmacol Sin Source Type: research
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Magazine Source Type: news
CONCLUSIONS: The USMA experience mirrored what was occurring in the larger U.S. Army in the early 20th century and may serve as a model for the application of NPIs in response to modern infectious diseases resulting from novel or unknown etiologies. PMID: 32870979 [PubMed - as supplied by publisher]
Source: Military Medicine - Category: International Medicine & Public Health Tags: Mil Med Source Type: research
The emergence of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) in China, reported to the World Health Organization on December 31, 2019, has led to a large global pandemic and is a major public health issue. As a result, there are more than 200 clinical trials of COVID-19 treatments or vaccines that are either ongoing or recruiting patients. One potential therapy that has garnered international attention is hydroxychloroquine; a potent immunomodulatory agent FDA-approved for the treatment of numerous inflammatory and autoimmune conditions, including malaria, lupus, and rheumatoid arthritis. Hydro...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Coronavirus disease 2019 (COVID-19) which is caused by the novel SARS-CoV-2 virus is a severe flu-like illness which is associated with hyperinflammation and immune dysfunction. The virus induces a strong T and B cell response but little is known about the immune pathology of this viral infection. Acute Plasmodium falciparum malaria also causes acute clinical illness and is characterized by hyperinflammation due to the strong production of pro-inflammatory cytokines and a massive activation of T cells. In malaria, T cells express a variety of co-inhibitory receptors which might be a consequence of their activation but also...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractThe current outbreak of the highly transmittable and life-threatening severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved rapidly and posed a global health emergency. Many clinical trials are now being conducted to test possible therapies. To assist this, virtual screening via molecular docking was performed on several FDA-approved drugs, previously used in epidemics, and the top ten compounds were selected. These ten well-characterized drugs, previously used to treat malaria and Ebola infections, were screened based on their interactions with the SARS-CoV-2 ACE2 receptor and 3C-like protease. ...
Source: Network Modeling Analysis in Health Informatics and Bioinformatics - Category: Bioinformatics Source Type: research
CONCLUSION: According to literature reports, chloroquine has been proved to have anti-SARS-CoV-2 effect in vitro and the potential mechanism of chloroquine in vivo. Pharmacokinetic characteristics and DDIs study are helpful to guide rational drug use in general and geriatric patients. Although there have been reports of successful clinical application of chloroquine in treatment COVID-19´╝îmore clinical test data are still needed to prove its effectiveness and safety. PMID: 32651961 [PubMed - as supplied by publisher]
Source: Current Drug Metabolism - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Metab Source Type: research
More News: Academies | Belgium Health | Coronavirus | COVID-19 | Hydroxychloroquine | International Medicine & Public Health | Malaria | SARS | Virology